Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Assets of the old GTEC:
We still hold shares in Lotus en Gold Horse, check it out:
Lotus : 3+ million
http://moneycentral.msn.com/ownership?Holding=5%25+Ownership&Symbol=LTUS
Gold Horse : 11+ million!
http://moneycentral.msn.com/ownership?Symbol=GHII
So there are still some assets left to be distributed to the pre-merger-shareholders. I am hoping to get some news on that soon. It was stated that would be explained in Oct. 2008!
Read here (page 4) http://www.pinksheets.com/edgar/GetFilingPdf?FilingID=5466600:
The Karmoya Shareholders have acknowledged that the current assets of Genesis will be distributed to the Genesis shareholders other than the
former Karmoya Shareholders and their assignees or transferees.
To be honest I don't know. The downward risk isn't big, the upside potential is huge. It could go lower than today's level but that will only be for a couple of days. I haven't changed my mind on what I have posted before:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=32221471
I expect the next move to happen this week or next week because then the numbers on FY2008 (ended June 30th '08) will be out.
Big, I didn't hear the CC so I don't really know. But said or not said, the truth is in this document:
http://www.pinksheets.com/edgar/GetFilingPdf?FilingID=5528538
Can this be the case? I really can't tell for sure.
In connection with the Offering, the Company’s principal stockholder placed in escrow 20,000,000 shares of Common Stock, which
shall be replaced by 20,000,000 shares issued by the Company in the name of the escrow agent, at which time the shares delivered by the
principal stockholder will be returned. In the event the Company’s consolidated Net Income Per Share (as defined in the Purchase Agreement),
for the year ended June 30, 2008 is less than $0.038, the escrow agent shall deliver the 20,000,000 shares to the Investor.
AS = 900 million / 40 = 22,55 million
Outstanding can be found above in ibox ?
Or here: http://www.pinksheets.com/pink/quote/quote.jsp?symbol=gnph
So that would make Outstanding: 10 million plus a little...
They are going to regret they let go of all these shares! Pope should have dumped other holdings, GNPH could have made them a lot of money.
Unless they know something we don't...
The page I linked to a few messages back states it as follows:
Pope Asset Management, L.L.C.
shares held 9,377 (in my opinion they still have these after they sold the majority)
shares sold 490,623
Together that totals up to 500,000 pre reverse split that makes 20 million exactly. This cannot be a coincidence. I say Pope has sold 98% of their shares, they went for the quick profit?
http://moneycentral.msn.com/ownership?Holding=Institutional+Ownership&Symbol=GNPH
Not 196 but 19.6 million and that is a number that sounds about familiar I guess (I believe 20 million mentioned somewhere in one of the deals...)
Somewhere in this document 20 million is mentioned:
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=5550661
But Randy it is stated Pope sold shares (or do I misinterpret the information?) Do you mean that in addition to the financing deal they bought extra shares and sold those?
If they sold that amount it would explain why the pps gradually got lower in may-june ?
Check out the following link:
http://moneycentral.msn.com/ownership?Holding=Institutional+Ownership&Symbol=GNPH
Can we conclude that Pope has sold a big part of their shares? I hadn't noticed this before? Did I miss it?
Shares have been absorbed by the market well then. No selling pressure to be expected then?
Doesn't matter, I was wondering. Enough offtopic for me now.
Can hardly wait to see the numbers on fiscal year 2008, we'll know within 2 weeks. Even more curious about news on the coming things:
- when will uplisting take place
- dividend of pre-merger GTEC assets
- release of the other 4 new drugs
Long are intentionally mixing me and bbb up?
Long here is my answer:
I have always seen the possibilities, that's why I have held on to my shares until now. But there where moments when I thought they couldn't get it worked out. Think about the financing deals, those surely weren't the best deals ever...
When authorized shares went up I was afraid they would dilute the hell out of us ... that would have left you and me and a lot of other people with nothing ...
There where months when there was no PR whatsoever, I then mailed to Ms. Sung and got no answer... ad all these things up and you see why I had doubts about the good outcome of it all...
I have (almost) no doubts left now. The question is when will we see that $50, $100? I think we will see the first mark before the end of this year.
How about GNPH? My guess is it could be a tenbagger within a year, see this posting. What do you think?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=32221471
In short:
It's a chinese pharma company. Supposedly trying to get uplisted on Nasdaq. In pipeline 4 new drugs. Fiscal year ended June 30th 2008, expectations on 100 million revenues and 26+ million profits. Numbers on FY2008 will be out soon (within 1~2 weeks).
GNPH going to $100 is that possible?
I think it is possible within one year from now:
Let's take the predicted 100 million revenues this year and add 30% growth, that makes 130 million revenues for fiscal year 2009.
Profit will be between 25-35% of that revenues, let's assume it will be 30% of 130 million. That means a profit of $ 39 million.
Assume there are 11 million shares outstanding next year (sept. '08 approx. 10.5 million). That means earnings per share 39 / 11 = $ 3.54.
If we multiply that with a PE of 30 (which is not impossible on Nasdaq for a very promising pharma company) we get an expected shareprice of $ 106.20
That means I am holding a tenbagger in my portfolio, I can't believe it !?!
Less positive outlook:
Let's take the predicted 100 million revenues this year and add 10% growth, that makes 110 million revenues for fiscal year 2009.
Profit will be between 25-35% of that revenues, let's assume it will be only 25% of 110 million. That means a profit of $ 27.5 million.
Assume there are 11 million shares outstanding next year (sept. '08 approx. 10.5 million). That means earnings per share 27.5 / 11 = $ 2.50.
If we multiply that with a PE of 20 (which is reasonable on Nasdaq for a pharma company) we get an expected shareprice of $ 50.00
Still not too bad!
John Wang owns no shares (yet), he is only a board member since a few days.
http://www.pinksheets.com/edgar/GetFilingPdf?FilingID=6154648
Yeah there is news:
http://biz.yahoo.com/prnews/080911/cnth027.html?.v=24
Orders worth of 12 million that is 10% already of what sold last year. Mark my words: fiscal year 2009 will be great!
Read message here:
Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
LAIYANG, China, Sept 11, 2008 /Xinhua-PRNewswire-FirstCall via COMTEX/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that the Company received purchase orders for a total value of approximately $12 million over the next 12 months from over 800 wholesale distributors at the 43rd Annual New Drugs Conference (the "Conference") sponsored by China Health Tech Forum 2008.
The 43rd Annual New Drugs Conference was held on September 3rd - 5th in Yantai International Expo Center, Shandong Province. The purpose of this industry Conference was to allow pharmaceutical companies in China with new and innovative products to meet and exchange ideas, and to allow pharmaceutical companies to introduce their products to distributors. Genesis distributed a large number of Company brochures at the Conference and received numerous inquiries from distributors.
The Company's newly developed Radix Isatidis Dispersible Tablets, an herbal-based traditional Chinese medicine, received the highest number of orders, over 60% of the total value of the purchase orders.
"We are pleased that the 43rd Annual New Drugs Conference was such a success for the Company. We believe that these new purchase orders from these distributors will increase our presence in the Chinese over the counter pharmaceuticals market," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "We hope to expand our market share and get even greater brand recognition in China in the future by bringing new and innovative products to market."
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung, CFO
Tel: +1-954-727-8435
Email: genesispharm@gmail.com
Web: http://www.genesis-china.net
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgir.com
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
URL: http://www.genesis-china.net
http://www.ccgir.com
www.prnewswire.com
Copyright (C) 2008 PR Newswire. All rights reserved
There is a lot more to be read here:
http://www.cchwallstreet.com/NASDAQTools/PlatformViewer.asp?selectednode=chp%5F1%5F1%5F4%5F1&manual=%2Fnasdaq%2Fmain%2Fnasdaq%2Dequityrules%2F
I really think none of us here can say for sure if GNPH already meets all the requirements. I think only experts (accountants/lawyers) can say so.
That's not easy to tell because there are a lot of things a company has to do. Read this and you know, I haven't read it all because there is an overwhelming amount of information.
http://www.nasdaq.com/about/LegalComplianceFAQs.stm
Or read this:
http://www.nasdaq.com/about/nasdaq_listing_req_fees.pdf
Maybe someone should call Ms. Sung or Mr. Coulson?
Don't worry all will be allright if GNPH gets the attention it deserves. Uplisting to Nasdaq = attention from major investors!
I think you are 100% right on that Bigplay777. They wouldn't make that statement if there was any doubt left. So the goal is clear: getting listed on Nasdaq, that almost "guarantees" at least a PE of 20 and therefore justifies a price per share of about $ 40. Since earnings will be at least 40 x $0.05 for fiscal year 2008. Let alone if we catch some growth and thus higher profits in fiscal year 2009 the pps could get a lot higher than $ 40. In that light $8 today is a bargain...I wish I had some liquidity.
Let me remindyou all that fiscal year 2009 has already started for GNPH as of June 30. '08!!
That's a long wait, but there is a positive side on that:
the numbers on the 1st quarter of fiscal year 2009 (quarter ending 30th Sept) are out only 6 weeks later!!
This means a lot of news the coming weeks, starting Sept 30th or maybe a few days earlier. Each time only a short period of silence in between them. Can't wait to see what that will do the pps!
I am confused, I have read about several things: 10 weeks after year-end, 90 days after year end. If you use 90 days after June 30th that makes end of September. Don't think that delay is granted because of R/S / symbolchange...
Aber wie immer ohne Gewähr.
Watch this:
How about nr. 2, I'll settle for that!
I have edited my earlier posted table. I have made 3 variations for 2008, with different ratio's for the PE. I think BigGreen101 might be right that projection foor 2008 was a little low.
Greetings from Holland and GLTA
Sure, we have to promote the new name! So watch this:
Keinen dank. I hope to get some comments from more savvy/experienced investors, but we'll see.
If this comes out like I've written down that would be great! Things can go fast now. They wouldn't RS and then wait another year to uplist. That's too risky. I expect news to follow up faster now than before.
My best guess for the pps in the future, any comments are welcome! I now remember why I am long on GNPH.
Greetings from Holland and GLTA
Come on _bbb_ let's bring on the train again as a sign of renewed trust and the beginning of a long journey to prosperity!!
To answer my own question:
Level 2 can be found here: http://www.allstocks.com/level2quotesotcbb1.html
Weathering the storm that's a nice way to put it and it has been what us longs have been doing here...
It is good people post not only the positive things they can find but also the negative things too, if the statements they post are true I mean. That is what a board should be all about: making each other wiser and helping to understand each other what is going on with our beloved stock, and look at the pro's and con's.
What's up with 15th April?
Does someone know where to find level 2 for free?
Greetings from Holland and GLTA
Ha that ain't nothing look at the ask price here:
http://finance.yahoo.com/q?s=GNPH.OB
(Yes it says 2000 dollar ?!)
My bank has written € 11.00 (~$15) off my account because of the reverse split?! Well I guess that is my contribution to get uplisted... LOL
Greetings from Holland and GLTA
This is a good summary of the last few months, including the Reverse split and the financing deals.
Read for yourself:
Quote
"Genesis Pharmaceuticals Enterprises (GNPH.OB) has effected a 40-to-1 reverse stock split and changed its ticker symbol to GNPH from the previous symbol GTEC. As before, Genesis Pharma trades on the OTC Bulletin Board Exchange. After the reverse split, Genesis has 10.3 million shares outstanding.
Cao Wubo, Chairman and CEO of Genesis, said in a statement that the reverse split was part of a strategic initiative to move its listing to a “senior” stock exchange in the US.
Before the reverse split, Genesis closed Wednesday night at 24 cents per share. This implies a post-split price of $9.60. However, three hours after the market opened, Genesis had not yet traded. It is listed as being bid at $5.25 with an ask of $22.00, a divide of truly Grand Canyon proportions. At a theoretical value of $9.60 and 10.3 million shares outstanding, Genesis Pharma has a market capitalization of $99 million.
Genesis Pharma became a publicly traded company in October of 2007 through a reverse merger. Its operational company, Laiyang Jiangbo Pharmaceuticals Co., Ltd. of Shandong, merged into Genesis Technology Group. In its short history, the company has engaged in a considerable amount of financial engineering, including a $30 million three-year note offering, completed in June of this year. The notes carry a 6% coupon and are convertible into stock at 20 cents per share, an unusually steep 3% discount to the price at the time of the offering. The convertible shares will add 3.75 million shares onto the number of shares outstanding.
The terms of the offering were dilutive to existing shareholders and would usually suggest a marginal enterprise that is desperate for cash at any price. But Laiyang Jiangbo is a robust and profitable pharmaceutical company. In the first nine months of its fiscal year (ended March 30, 2008), the company produced net income of $12.9 million on revenues of $66.6 million.
Approximately 67% of its revenues come from western-style drugs while the remainder derives from traditional Chinese medicines. Its top four products in fiscal 2007 were Clarithromycin sustained-release tablets (antibiotic), Itopride Hydrochloride granules (a digestive aid), Ciprofloxacin Hydrochloride tablets (bacterial antibiotic), and Paracetamol tablets (analgesic for flu). Laiyang Jiangbo spent a fairly substantial $2.2 million in the first nine months of the year on R&D.
In November 2007, Laiyang Jiangbo used the majority of a $5 million private placement to buy the patent on a new cerebral vascular medicine, currently undergoing testing in China. The drug, Ligustrazine Ferulic Acid Acetate [LFAA], works to reduce blood clotting and prevent platelets from clumping together. LFAA is classified as Chinese Class 1 compound, which means that it has never been imported to China nor marketed elsewhere in the world. Assuming the drug is granted marketing approval by the SFDA, Genesis will put LFAA into trial production in 2008 and begin marketing the drug in 2009.
Disclosure: none."
Unquote
Link:
http://seekingalpha.com/article/94036-genesis-pharma-completes-40-to-1-reverse-split?source=yahoo
Greetings from Holland and GLTA
Okay we are halfway now, some shares traded at 11.00$! Go go go to 21$
My expectations for the coming months:
- numbers on FY 2008, probably won't be a lot of surprises
- news on new drug(s)
- news on uplisting
- news on dividend (probably will be zero, but news is due Oct 2008?)
But sofar no trade took place?
Guess people first want to see the numbers on FY 2008. Maybe tomorrow?
Oh what, I'll even sell my shares for $21 a piece! If that would come true
bid 5.25 vs. ask 22
that is biiiig spread
on yahoo ?
Greetings from Holland and GLTA
Copy/paste from mailbox:
Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
LAIYANG, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a leading pharmaceutical company in the People¡¯s Republic of China, today announced that it completed a 40-for-1 reverse stock split of its common stock which will begin trading under the symbol "GNPH."
Upon today¡¯s market open, Genesis¡¯ common stock will no longer trade under the symbol "GTEC" and will begin trading on a split-adjusted basis under the trading symbol "GNPH."
Following this reverse stock split, the Company has approximately 10,325,000 shares of common stock outstanding.
"We are pleased to complete this reverse stock split of our common stock as part of our efforts to position the company to move to a senior U.S. stock market and improve the marketability and value of our shares," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "We expect this adjustment to our capital structure to bring the Company to the attention of new investors and make our shares more attractive to them."
Stockholders who hold their shares in brokerage accounts or "street name" will not be required to take any action to exchange their shares. Stockholders of record who hold share certificates will receive a letter of transmittal requesting that they surrender their old stock certificates for new stock certificates reflecting the adjusted number of shares as a result of the reverse stock split. The Transfer Agent and Registrar for shares of GTEC¡¯s common stock is Computershare Trust Company, 350 Indiana St., #800, Golden, Colorado 80401, (303) 262-0600. They will act as the exchange agent for purposes of implementing the exchange of stock certificates.
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People¡¯s Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal-based medical drugs.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company¡¯s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company¡¯s ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company¡¯s ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company¡¯s business and financial results is included in the Company¡¯s filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung, CFO
Tel: +1-954-727-8435
Email: genesispharm@gmail.com
Web: http://www.genesis-china.net
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgir.com
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
-0- 09/04/2008
/CONTACT: Genesis Pharmaceuticals Enterprises, Inc. - Ms. Elsa Sung, CFO, +1-954-727-8435, or genesispharm@gmail.com, CCG Investor Relations, Inc. - Mr. Crocker Coulson, President, +1-646-213-1915, or crocker.coulson@ccgir.com, for Genesis Pharmaceuticals Enterprises /
/Web site: http://www.genesis-china.net
http://www.ccgir.com /
(GNPH)
You are receiving this transmission from PR Newswire on behalf of the issuer of the information contained in this email. If you would like to stop receiving information of this nature via email for this issuer, click here, for auto-removal.
Greetings from Holland and GLTA
That is what I was thinking about earlier (check: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=31915349). But you never know since we haven't seen PR or guidance of any kind...
I am betting that at first the PPS will get lower. It starts with 0.24 x 40 = $ 9.6. But since R/S without further PR/guidance is usually only the predictor of further dilution, I think pps will drop at first. We need a PR on the reasons why they split 40-1...